Skip to main content

Main menu

  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Blog
    • Collections
    • Podcast
  • TOPICS
    • Cognition and Behavior
    • Development
    • Disorders of the Nervous System
    • History, Teaching and Public Awareness
    • Integrative Systems
    • Neuronal Excitability
    • Novel Tools and Methods
    • Sensory and Motor Systems
  • ALERTS
  • FOR AUTHORS
  • ABOUT
    • Overview
    • Editorial Board
    • For the Media
    • Privacy Policy
    • Contact Us
    • Feedback
  • SUBMIT

User menu

Search

  • Advanced search
eNeuro

eNeuro

Advanced Search

 

  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Blog
    • Collections
    • Podcast
  • TOPICS
    • Cognition and Behavior
    • Development
    • Disorders of the Nervous System
    • History, Teaching and Public Awareness
    • Integrative Systems
    • Neuronal Excitability
    • Novel Tools and Methods
    • Sensory and Motor Systems
  • ALERTS
  • FOR AUTHORS
  • ABOUT
    • Overview
    • Editorial Board
    • For the Media
    • Privacy Policy
    • Contact Us
    • Feedback
  • SUBMIT
PreviousNext
Research ArticleResearch Article: New Research, Disorders of the Nervous System

Use of a Self-Delivering Anti-CCL3 FANA Oligonucleotide as an Innovative Approach to Target Inflammation after Spinal Cord Injury

Nicolas Pelisch, Jose Rosas Almanza, Kyle E. Stehlik, Brandy V. Aperi and Antje Kroner
eNeuro 25 February 2021, 8 (2) ENEURO.0338-20.2021; DOI: https://doi.org/10.1523/ENEURO.0338-20.2021
Nicolas Pelisch
1Department of Neurosurgery, Medical College of Wisconsin, Milwaukee, WI 53226
3Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee, WI 53295
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jose Rosas Almanza
1Department of Neurosurgery, Medical College of Wisconsin, Milwaukee, WI 53226
3Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee, WI 53295
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kyle E. Stehlik
1Department of Neurosurgery, Medical College of Wisconsin, Milwaukee, WI 53226
3Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee, WI 53295
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brandy V. Aperi
1Department of Neurosurgery, Medical College of Wisconsin, Milwaukee, WI 53226
3Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee, WI 53295
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antje Kroner
1Department of Neurosurgery, Medical College of Wisconsin, Milwaukee, WI 53226
2Department of Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, WI 53226
3Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee, WI 53295
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Figures & Data

Figures

  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    FANA ASO molecules penetrate BMDMs in a gymnotic fashion and reduce CCL3 expression in vitro. A, When added to the tissue culture media, fluorescently labeled FANA ASO molecules penetrate BMDM cells after 2 h of incubation (red fluorescence, lower panel). The upper panel demonstrates the absence of fluorescence when no FANA ASO molecules were added to the media. Scale bar: 50 μm. B, Assessment of CCL3 knock-down in LPS stimulated BMDMs using four different FANA ASOs molecules. CCL3 mRNA expression levels were compared between LPS-treated BMDMs in the presence of scrambled control FANA ASO or the individual anti-CCL3 FANA ASOs. CCL3 expression levels were unchanged in the presence of FANA-CCL3#1, FANA-CCL3#2, and FANA-CCL3#3. Treatment with FANA-CCL3#4 resulted in a significant reduction of CCL3 expression by ∼80%. Untreated BMDMs are included for reference; n = 3/group; *p < 0.05. Error bars are represented as SEM.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Fluorescently labeled FANA ASOs are present at the SCI lesion site after intrathecal injection. A, Representative images of flow cytometry on cells from a section of spinal cord tissue centering on the lesion or spinal cord tissue from naive mice. Green fluorescence derived from FAM-labeled FANA was detectable in gated cell populations for CD11b+/CD45low microglia (MG) and CD11b+/CD45high MDMs. MDM are not detected in naive tissue. B, Quantification of percentages of MG and MDM containing FAM-labeled FANA; n = 4/group, error bars are represented as SEM. C, Seven days after SCI and intrathecal injection, labeled FANA ASO was detectable at the lesion site (red staining). Confocal images with orthogonal view demonstrate uptake of FANA molecules in a non- cell specific manner, as shown by the presence in CD11b+ macrophages/microglia and GFAP+ astrocytes. No uptake was detected in NeuN+ neurons; n = 4–5/group. Scale bars: 80 μm.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    CCL3 expression levels following SCI were reduced after FANA ASO injection. A, A single injection of FANA ASO CCL3#4 resulted in significant suppression of CCL3 mRNA expression in the injured spinal cord compared with scrambled control at day 3 postinjury. This reduction was accompanied by the suppression of TNF and IL-1β expression, indicating a reduction of the proinflammatory tissue reaction. B, When using a two-injection paradigm, CCL3, TNF, and IL-1β mRNA were also suppressed at day 3. C, When three doses were administered, a sustained suppression of CCL3 was detected at day 7, reducing CCL3 levels by ∼60%. Both TNF and IL-1β gene expression levels were reduced by ∼50%. D, Suppression of CCL3 and TNF in the injured spinal cord was also measured the protein level using ELISA at days 1, 3, and 7 and days 1 and 3 after SCI, respectively; n = 5/group; +++p < 0.001 (compared with laminectomy control); *p < 0.05, ***p < 0.001 (compared with scrambled control of the same time point). Error bars are represented as SEM.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Treatment with anti-CCL3 FANA ASO resulted in mild functional improvement. A, BMS scores did not show significant improvement compared with control animals when anti CCL3-FANA was administered three times starting right after injury. B, However, a significantly higher percentage of CCL3-FANA ASO-treated mice performed plantar placement on days 5–7 after injury, compared with control animals. To ensure sufficient time to knock-down CCL3, we also investigated the efficacy of CCL3-FANA ASO pretreatment, with the first dose given 24 h before injury, followed by two more injection immediately after injury and 24 h later. C, BMS scores were not significantly different in treated versus control animals when anti CCL3-FANA was administered three times starting 24 h before injury. D, The pretreatment group, however, showed a significant increase of plantar placement at days 3 through 7 after injury compared with controls; n = 10/group in preinjury treatment paradigm, n = 12/group in postinjury treatment. Data points are represented as mean ± SEM. Note that bars in B, D represent the total percentage of mice from each group capable of plantar placement, thereby not allowing for error bars; *p < 0.05, χ2 test.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Treatment with anti-CCL3 FANA ASOs reduced CD11b+ macrophages at the lesion site. A, B. Flow cytometry 1 d after SCI in anti-CCL3-FANA ASO and control-treated animals did not reveal a significant difference in Gr-1+ neutrophils. Numbers were assessed in the CD11b+CD45+ gated cell population. The negative control was stained with CD11b+CD45+ in absence of the Gr-1 antibody. A, Representative flow cytometry images. B, Quantification of CD11b+CD45+Gr-1+ neutrophils. C, Representative images of CD11b+ macrophages/microglia, GFAP+ astrocytes, and SMI-32+ profiles as indicators of axonal damage adjacent to the lesion epicenter in anti-CCL3-FANA ASO and control-treated animals. The schematic indicates the location of the quantified region (square) next to the lesion (red circle). D, Quantification revealed a significant reduction of CD11b+ macrophages/microglia in the anti-CCL3-FANA ASO treatment group, while neither astrocytes nor indicators of axonal damage were different between groups; n = 5/group, data points are represented as mean ± SEM; *p = 0.01. Scale bars: 80 μm.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    CCL3 inhibition with FANA ASOs did not significantly reduce tissue damage after SCI. Quantification of areas devoid of GFAP immunoreactivity at day 28 after SCI did not show a significant difference in lesion area in anti-CCL3-FANA ASO-pretreated mice compared with control mice. A, Representative images of GFAP and FluoroMyelin stained spinal cord cross sections. B, Quantitative analysis of the lesion volume in CCL3-FANA ASO-pretreated mice and control mice. C, No differences in myelin content, as shown with FluoroMyelin Red staining, were detected between groups; n = 9/group. Data points are represented as mean ± SEM. Scale bars: 500 μm.

Back to top

In this issue

eneuro: 8 (2)
eNeuro
Vol. 8, Issue 2
March/April 2021
  • Table of Contents
  • Index by author
  • Ed Board (PDF)
Email

Thank you for sharing this eNeuro article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Use of a Self-Delivering Anti-CCL3 FANA Oligonucleotide as an Innovative Approach to Target Inflammation after Spinal Cord Injury
(Your Name) has forwarded a page to you from eNeuro
(Your Name) thought you would be interested in this article in eNeuro.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
View Full Page PDF
Citation Tools
Use of a Self-Delivering Anti-CCL3 FANA Oligonucleotide as an Innovative Approach to Target Inflammation after Spinal Cord Injury
Nicolas Pelisch, Jose Rosas Almanza, Kyle E. Stehlik, Brandy V. Aperi, Antje Kroner
eNeuro 25 February 2021, 8 (2) ENEURO.0338-20.2021; DOI: 10.1523/ENEURO.0338-20.2021

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Use of a Self-Delivering Anti-CCL3 FANA Oligonucleotide as an Innovative Approach to Target Inflammation after Spinal Cord Injury
Nicolas Pelisch, Jose Rosas Almanza, Kyle E. Stehlik, Brandy V. Aperi, Antje Kroner
eNeuro 25 February 2021, 8 (2) ENEURO.0338-20.2021; DOI: 10.1523/ENEURO.0338-20.2021
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Significance Statement
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
    • Synthesis
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Keywords

  • CCL3
  • FANA ASO
  • inflammation
  • novel RNA inhibitor
  • secondary damage
  • spinal cord injury

Responses to this article

Respond to this article

Jump to comment:

No eLetters have been published for this article.

Related Articles

Cited By...

More in this TOC Section

Research Article: New Research

  • MEG Activity in Visual and Auditory Cortices Represents Acoustic Speech-Related Information during Silent Lip Reading
  • Postnatal Development of Projections of the Postrhinal Cortex to the Entorhinal Cortex in the Rat
  • Dendritic Compartmentalization of Learning-Related Plasticity
Show more Research Article: New Research

Disorders of the Nervous System

  • NEURONAL CORRELATES OF HYPERALGESIA AND SOMATIC SIGNS OF HEROIN WITHDRAWAL IN MALE AND FEMALE MICE
  • Visual System Hyperexcitability and Compromised V1 Receptive Field Properties in Early-Stage Retinitis Pigmentosa in Mice
  • 14-3-3θ Does Not Protect against Behavioral or Pathological Deficits in Alzheimer’s Disease Mouse Models
Show more Disorders of the Nervous System

Subjects

  • Disorders of the Nervous System

  • Home
  • Alerts
  • Visit Society for Neuroscience on Facebook
  • Follow Society for Neuroscience on Twitter
  • Follow Society for Neuroscience on LinkedIn
  • Visit Society for Neuroscience on Youtube
  • Follow our RSS feeds

Content

  • Early Release
  • Current Issue
  • Latest Articles
  • Issue Archive
  • Blog
  • Browse by Topic

Information

  • For Authors
  • For the Media

About

  • About the Journal
  • Editorial Board
  • Privacy Policy
  • Contact
  • Feedback
(eNeuro logo)
(SfN logo)

Copyright © 2022 by the Society for Neuroscience.
eNeuro eISSN: 2373-2822

The ideas and opinions expressed in eNeuro do not necessarily reflect those of SfN or the eNeuro Editorial Board. Publication of an advertisement or other product mention in eNeuro should not be construed as an endorsement of the manufacturer’s claims. SfN does not assume any responsibility for any injury and/or damage to persons or property arising from or related to any use of any material contained in eNeuro.